Mankind Pharma Ltd announced on October 29, 2025, that CRISIL Ratings has withdrawn the credit rating on their bank loan facilities of 1,250 crore and reaffirmed ratings for non-convertible debentures of 400 crore and 4,600 crore, along with commercial paper reduced from 5,000 crore to 1,500 crore.